The BIOSECURE Act of 2025 would bar federal executive agencies from buying biotechnology equipment or services from designated “biotechnology companies of concern,” and would also prohibit agencies from using loan or grant funds for those same products or services. It would further prevent agencies from contracting with entities that use covered biotechnology equipment or services in performing federal work, if those products or services were acquired after the bill’s effective date. The bill is aimed at limiting federal dependence on biotechnology providers tied to foreign adversaries or otherwise viewed as posing national security risks.
The bill creates a process for the Office of Management and Budget, working with multiple national security, defense, health, commerce, and intelligence agencies, to publish and update a list of covered companies. A company can be covered if it is identified as a Chinese military company operating in the United States or if it meets criteria tied to foreign adversary control, involvement in biotechnology, and national security risk, including joint research with adversary military or intelligence services, sharing multiomic data with a foreign adversary, or obtaining human multiomic data without express informed consent. The bill also directs the intelligence community to assess risks from foreign adversary acquisition of American multiomic data and requires reporting on nefarious activities involving such data.
The bill would affect federal procurement, grants, and loans, as well as contractors and subcontractors that rely on covered biotechnology products or services. It includes phased effective dates, grandfathering for certain preexisting contracts for up to five years, and a safe harbor for products or services that are no longer supplied by a covered company. It also requires the Federal Acquisition Regulatory Council to revise the Federal Acquisition Regulation to implement the restrictions, and it authorizes no additional appropriations for carrying out the section.
The bill’s overall sentiment appears strongly security-focused and precautionary, with the sponsors framing it as a response to national security and data-security concerns involving foreign adversaries and sensitive biological information. Because there are no recorded votes or committee transcripts in the provided context, there is no evidence of organized opposition or support in the available materials beyond the bill’s introduction and referral. The structure of the bill suggests an intent to balance restrictions with limited waivers and exceptions for intelligence activities, overseas health care, public health emergencies, and certain preexisting arrangements.
Notable points of contention likely center on the breadth of the definition of covered biotechnology companies, the reach of the procurement and grant prohibitions, and the treatment of multiomic data and informed consent. Potential concerns include compliance burdens for federal agencies and contractors, possible disruption to existing supply chains, and the risk that national security screening could sweep in entities with indirect or limited ties to foreign adversaries. At the same time, supporters would likely emphasize the bill’s waivers, exceptions, and notice-and-review procedures as safeguards against overreach.
The bill would add a new federal procurement and funding restriction regime targeting biotechnology equipment and services linked to designated foreign-adversary-related companies. It would require executive agencies to avoid covered biotechnology providers, direct OMB and other agencies to create and maintain a designation process and guidance, and compel FAR revisions to implement the new rules. The measure would also influence contractors, grant recipients, and loan recipients, while creating reporting obligations for the intelligence community and limited exceptions for intelligence work, overseas health care, and emergency medical countermeasures.
The available context suggests the bill is generally framed in a favorable, national-security-oriented light by its sponsors, with an emphasis on protecting federal systems and sensitive biological data from foreign adversary influence. No committee debate or vote record is provided, so there is no documented bipartisan or partisan split in the materials. The bill’s design, including waivers and exceptions, indicates an effort to present the restrictions as targeted rather than absolute.
The main points of contention are likely to be the scope of the term “biotechnology company of concern,” the inclusion of companies tied to foreign adversaries through ownership, research, or data practices, and the practical impact on federal procurement and contractor supply chains. Another likely issue is the treatment of human multiomic data and whether the bill could affect legitimate research, diagnostics, or commercial services. Supporters would likely prioritize national security and data protection, while critics may focus on overbreadth, implementation complexity, and possible disruption to health care, research, and existing contracts.